AgnandjiSTHuttnerAZinserME. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe—preliminary report. N Engl J Med. Epub ahead of print 1 April 2015. DOI: 10.1056/NEJMoa1502924.
2.
LedgerwoodJEDeZureADStanleyDA. Chimpanzee adenovirus vector Ebola vaccine—preliminary report. N Engl J Med. Epub ahead of print 26 November 2014. DOI: 10.1056/NEJMoa1410863.
HuttnerADayerJAYerlyS. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis2015; 15: 1156–1166.
5.
BellanSEPulliamJRPearsonCA. Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis. Lancet Infect Dis2015; 15: 703–10.
6.
BrownCALilfordRJ.The stepped wedge trial design: a systematic review. BMC Med Res Methodol2006; 6: 54.
7.
KennedySBNeatonJDLaneHC. Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: design, procedures & challenges. Clin Trials2016; 13: 49–56.
Ebola ca Suffit Ring Vaccination Trial Consortium. The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. BMJ2015; 351: h3740.
11.
Henao-RestrepoAMLonginiIMEggerM. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet2015; 386: 857–866.
